A5033680248- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Microtubule and mitosis dynamics
- Cellular transport and secretion
- CAR-T cell therapy research
- Cellular Mechanics and Interactions
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Renal and related cancers
- Multiple and Secondary Primary Cancers
- Biotin and Related Studies
Institut Paoli-Calmettes
2016-2025
Inserm
2015-2024
Aix-Marseille Université
2015-2024
Centre de Recherche en Cancérologie de Marseille
2015-2024
Institut Pprime
2021-2024
Centre National de la Recherche Scientifique
2015-2022
Hôpital de la Timone
2019-2020
The Alfred Hospital
2012-2013
Hôpital Arnaud de Villeneuve
2012-2013
Objectives Immune Checkpoint Inhibitors (ICI) are nowadays a cornerstone of anti-cancer treatments. However, the wide spectrum immune-related adverse events (irAEs) represents challenge in oncological practice. Our objective is to document rare complications ICI help community onco-immunologists. Methods We reported case severe myositis mimicking bulbar palsy treated our Medical Oncology Department together with Internal Medicine Department. present clinical work-up (neurological exam,...
After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX regimen has been shown to be more effective than GEM-based regimens, it is also associated higher toxicity. Current treatment decisions based on patient performance status rather molecular characteristics tumor. To address this gap, goal study was develop...
596 Background: Biliary tract cancers (BTCs) are rare and heterogeneous tumors with a poor survival even in early-stage patients treated curative surgery. Since 2019 the current standard of care adjuvant setting is oral chemotherapy (CT) capecitabine for 6 months, as an option following BILCAP phase III trial results. Nevertheless, outside this trial, real-world data lacking. Methods: We conducted French, retrospective, multicenter study from ACABi-PRONOBIL cohort. Eligible had intrahepatic,...
Abstract Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors pembrolizumab in patients with advanced NSCLC. Experimental Design: We used high-dimensional mass cytometry (CyTOF) baseline blood samples NSCLC treated pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and...
Pancreatic cancer is a rising cause of death. Therapeutic options are scarce and limited efficacy. Up to 26% patients with metastatic pancreatic could benefit from targeted therapies. We report here for the first time case three ductal adenocarcinoma (PDAC) without KRAS alteration whom an activating mutation in exon 19 epidermal growth factor receptor (EGFR) gene was found through mainstreaming NGS. The EGFR variant confirmed on multiple tumor samples by circulating DNA (ctDNA) analysis two...
We hypothesized that a reduced potential for bronchiolar stem-cell (Clara cell)-related repair in the setting of an ever-present risk small airway injury would increase bronchiolitis obliterans syndrome (BOS).CCSP A38G gene polymorphism was assessed both lung donors and recipients longitudinal study cohort 63 consecutive transplant (LTR) with median follow-up 493 days (range, 26-894). Clara cell secretory protein (CCSP) interleukin 8 levels were bronchoalveolar lavage plasma at 1, 3, 6, 12...
To evaluate gemcitabine efficacy in advanced pancreatic cancer patients after the FOLFIRINOX regimen. Patients with locally-advanced or metastatic adenocarcinoma from French and Canadian centers, who were treated first-line regimen (FFX L1), followed by monotherapy as a second-line treatment (GEM L2), retrospectively evaluated. Statistical analyses performed on demographic, toxicity, response rate data. Overall survival (OS) progression-free (PFS) assessed using Kaplan–Meier method....
// Brice Chanez 1,2,3,4 , Anthony Gonçalves Ali Badache and Pascal Verdier-Pinard 1 Centre de Recherche en Cancérologie Marseille, Inserm, France 2 Institut Paoli-Calmettes, 3 Aix-Marseille Université, 4 CNRS, UMR7258, F-13009, Correspondence to: Verdier-Pinard, email: Badache, Keywords : eribulin, migration, microtubule, ch-TOG, EB1 Received June 18, 2015 Accepted September 30, Published October 19, Abstract Non-cytotoxic concentrations of microtubule targeting agents (MTAs) interfere with...
4569 Background: Although inhibition of PD-1/PD-L1 and MET receptors have clinical efficacy in mRCC, their expression is not a predictive biomarker. Heterogeneity between the sites disease might be one explanation. The aim our study was to evaluate PD-L1 primary metastases (brain (BM)/pancreas (PM)) RCC lesions correlation with clinicopathologic characteristics. Methods: specimen from different institutions were collected. Clinicopathologic characteristics assessed by revision samples. tumor...
Abstract Metastatic progression is the leading cause of mortality in breast cancer. Invasive tumor cells develop invadopodia to travel through basement membranes and interstitial matrix. Substantial efforts have been made characterize molecular composition. However, their full identity still missing due difficulty isolating them. To fill this gap, we developed a non-hypothesis driven proteomic approach based on BioID proximity biotinylation technology, using invadopodia-specific protein...
Background: Pancreatic metastases (PM) from renal cell carcinoma (RCC) are rare, associated with favorable outcomes and usually handled by surgery or VEGFR inhibitors, which both have side effects. Endoscopic Ultrasound (EUS)-guided radiofrequency ablation (RFA) is an innovative approach to treat focally deep could be a relevant technique control PM RCC. Methods: This monocentric, prospective study aimed evaluate the safety efficacy of EUS-RFA PM. We included patients confirmed progressive...
BACKGROUND: Neoadjuvant chemoradiotherapy followed by radical surgery is the standard curative treatment for mid- to low-rectal cancer. However, combination of these treatments may affect patients’ GI and genitourinary functions their quality life. In cases good clinical response neoadjuvant treatment, local excision a rectal sparing strategy that would limit side effects. OBJECTIVE: The aim this study compare effects or conventional laparoscopic total mesorectal after in patients with...
The development of immune checkpoint inhibitors (ICI) has dramatically changed the landscape therapies for metastatic renal cell carcinoma. However, many patients do not benefit from such therapy and prognostic or predictive validated biomarker ICI are still needed to better select treat patient. Plasmatic soluble checkpoints have been described as potential biomarkers in hematological malignancies solids tumors, then, we would like explore value different with mRCC treated nivolumab after...
Pancreatic ductal adenocarcinoma (PDAC) patients are frequently treated by chemotherapy. Even if personalized therapy based on molecular analysis can be performed for some tumors, PDAC regimens selection is still mainly patients' performance status and expected efficacy. Therefore, the establishment of predictors chemotherapeutic efficacy could potentially improve prognosis tailoring treatments. We have recently developed an RNA-based signature that predicts adjuvant gemcitabine using 38...
Neurological immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI) are rare complications of immunotherapy, particularly dreadful for patients and clinical teams. Indeed, neurological irAEs potentially severe their diagnosis require prompt recognition treatment. Additionally, the spectrum is broad, affecting either neuromuscular junction, peripheral or central nervous system. Here, we described case a 55-year man with metastatic melanoma, facing brutal right...
Background Dysthyroidism (DT) is a common toxicity of immune checkpoint inhibitors (ICIs) and prior work suggests that dysthyroidism might be associated with ICI efficacy. Patients methods ConSoRe, new generation data mining solution, was used in this retrospective study, to extract from electronic patient records adult cancer patients treated at Institut Paoli-Calmettes (Marseille, France). Every DT verified only ICI-induced retained. Survival analyses were performed by Kaplan-Meier method...
We aimed to identify genomic drivers of glioblastoma inevitable recurrence.Ten pairs initial and recurrent frozen IDHwt samples were screened by CGH Array. Next Generation Sequencing (NGS) was then performed on an enriched cohort 19 pairs. MPDZ alterations analyzed using TCGA dataset.Nineteen patients included. Median age 54.5 y/o (37.2-72.8). Using array, unsupervised analysis aggregated the paired tumors. Only 44% Array conserved at recurrence (amplifications: 55%; deletions: 30%). Two...
Regulation of microtubule dynamics by plus-end tracking proteins (+TIPs) plays an essential role in cancer cell migration. However, the +TIPs invasion has been poorly addressed. Invadopodia, actin-rich protrusions specialized extracellular matrix degradation, are for and metastasis, leading cause death breast cancer. We, therefore, investigated End Binding protein, EB1, a major hub +TIP network, invadopodia functions. EB1 silencing increased degradation cells. This was recapitulated...